About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Letter to the Editor
John A. Frantz, MD
Health Care and Law
Dr. Field discusses the trend of states allowing psychologists to prescribe psychotropic medications.
Robert I. Field, JD, MPH, PhD
Author: Debra Niehoff, PhD
Reviewed by Mark Noble, PhD
Evaluation of Three 5-HT3 Receptor Antagonists in the Prevention of Postoperative Nausea and Vomiting in Adults
The authors compare the efficacy of three antiemetic medications for PONV: ondansetron (Zofran®), granisetron (Kytril®), and dolasetron (Anzemet®).
Shan Wang, PharmD, Joseph Greco, MD, Reena A. Joseph, PharmD Candidate, Martin Feuerman, MS, and Brian Malone, MS
Consensus Panel Recommendations for the Assessment and Management of Breakthrough Pain. Part 2 Management
The authors continue their discussion of pharmacological and nonpharmacological therapies with a focus on criteria for the best agent, the subtypes of breakthrough pain, and the economic and quality-of life considerations.
Daniel Bennett, MD, Allen W. Burton, MD, Scott Fishman, MD, Barry Fortner, PhD, Bill McCarberg, MD, Chris Miaskowski, PhD, RN, David Nash, MD, MBA, Marco Pappagallo, MD, Richard Payne, MD, James Ray, PharmD, Eugene R. Viscusi, MD, and Winston Wong, PharmD
David Nash, MD, MBA, describes the mission and
vision of the International Society for Pharmacoeconomics & Outcomes Research (ISPOR) upon the occasion of its 10th anniversary.
David Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, discusses some common and dangerous problems associated with the dosing of epinephrine and other drugs used for resuscitating patients.
Matthew Grissinger, RPh, FASCP
Stephen Barlas comments on the refusal of the Centers for Medicare & Medicaid Services to fund pharmacy residents in their second year of training.
The authors review the benefits of ezetimibe/simvastatin (Vytorin®) as a therapeutic approach for hyperlipidemia.
Katrina Touchstone, PharmD Candidate, Laura Stark, PharmD Candidate, Marlon Honeywell, PharmD, Marvin Scott, PharmD, and Evans Branch III, PharmD
P&T presents the latest studies and information about FDA approvals, drug indications, industry updates, and new devices.